Brief: Jw Therapeutics Announces NMPA Approval Of Relmacabtagene Autoleucel Injection In Patients With Relapsed Or Refractory Follicular Lymphoma
10/10/2022 13:09
Oct 10 (Reuters) - JW (Cayman) Therapeutics Co Ltd
2126.HK :
* JW THERAPEUTICS ANNOUNCES NMPA APPROVAL OF RELMACABTAGENE
AUTOLEUCEL INJECTION IN PATIENTS WITH RELAPSED OR REFRACTORY
FOLLICULAR LYMPHOMA
Source text for Eikon: ID:nPnbB6ZFja
Further company coverage: 2126.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on JW (Cayman) Therapeutics Co
See all newsChina pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says
Brief: JW (Cayman) Therapeutics Appoints Tian Feng As CEO, Executive Director
Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment
Brief: JW (Cayman) Therapeutics H1 Net Income RMB -267.3 Million
Brief: JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License